Bimekizumab On-Treatment Remission as Defined by the National Psoriasis Foundation: 1-Year Results Versus Ustekinumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis
SKIN The Journal of Cutaneous Medicine · 14.07.2026 · 10 (4) · s798
DOI: 10.25251/1b4a6w73 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 14.07.2026. Verfasst von April Armstrong und 12 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Defining psoriasis remission is important for benchmarking responses and facilitating common understanding of a state where patients experience little/no diseaseA National Psoriasis Foundation (NPF) consensus definition of on-treatment remission in psoriasis has recently emerged: continuous maintenance of either body surface area (BSA)=0% for ≥6 months or Investigator’s Global Assessment (IGA)=0 for ≥6 months while on treatment (referred to here as NPF-defined remission).1 We aimed to apply the NPF definition of on-treatment remission for psoriasis to data from two head-to-head phase 3/3b trials, which evaluated bimekizumab vs ustekinumab and bimekizumab vs secukinumab over 1 year. Here, we report proportions of patients who achieved on-treatment remission at the earliest possible timepoint at which remission could be observed (Week 28; after 7 months of treatment). Procedure/Study Patients who completed the double-blinded periods of BE VIVID (52 weeks)/BE RADIANT (48 weeks) were included. In BE VIVID, patients were randomized to bimekizumab 320mg every 4 weeks (Q4W) or ustekinumab 45/90mg (≤100kg/>100kg) at Week 0, Week 4, then Q12W.2 In BE RADIANT, patients were randomized to bimekizumab Q4W to Week 16, then Q4W or Q8W thereafter, or secukinumab 300mg weekly to Week 4 then Q4W;3 bimekizumab Q4W and Q8W data were pooled. Proportions achieving NPF-defined remission (either continuous BSA=0% for ≥6 months or IGA=0 for ≥6 months) during the first year of BE VIVID/BE RADIANT, with no missing BSA/IGA measurements, are reported (observed cases).
Results
In BE VIVID/BE RADIANT, 64.9%/62.6% bimekizumab-treated (N=242/N=289) vs 30.0% ustekinumab-treated (N=120)/45.4% secukinumab-treated (N=260) patients achieved NPF-defined remission during any ≥6-month period in Year1. At Week 28, the earliest timepoint at which remission could be observed in BE VIVID/BE RADIANT, 12.4%/10.4% bimekizumab-treated vs 0% ustekinumab-treated/3.8% secukinumab-treated patients achieved remission. At Year1, 55.8%/57.4% bimekizumab-treated vs 26.7% ustekinumab-treated/40.8% secukinumab-treated patients achieved remission.
Conclusion
Higher proportions of bimekizumab-treated patients achieved NPF-defined on-treatment remission than ustekinumab-/secukinumab-treated patients from Week 28 (earliest timepoint at which remission could be observed) through Year1.
Zitieren
APA
Armstrong, A., Pérez-Chada, L., Lebwohl, M., Balak, D. M., Lewitt, G. M., Warren, R. B., Langley, R. G., Thaçi, D., Han, G., Herr, H., Szilagyi, B., Kavanagh, S., & Blauvelt, A. (2026). Bimekizumab On-Treatment Remission as Defined by the National Psoriasis Foundation: 1-Year Results Versus Ustekinumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine, 10(4), s798. https://doi.org/10.25251/1b4a6w73
Vancouver
Armstrong A, Pérez-Chada L, Lebwohl M, Balak DM, Lewitt GM, Warren RB, et al. Bimekizumab On-Treatment Remission as Defined by the National Psoriasis Foundation: 1-Year Results Versus Ustekinumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine. 2026;10(4):s798. doi:10.25251/1b4a6w73
BibTeX
@article{Armstrong2026,
author = {Armstrong, April and Pérez-Chada, Lourdes and Lebwohl, Mark and Balak, Deepak M.W. and Lewitt, George M. and Warren, Richard B. and Langley, Richard G. and Thaçi, Diamant and Han, George and Herr, Heather and Szilagyi, Balint and Kavanagh, Sarah and Blauvelt, Andrew},
title = {Bimekizumab On-Treatment Remission as Defined by the National Psoriasis Foundation: 1-Year Results Versus Ustekinumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {4},
pages = {s798},
doi = {10.25251/1b4a6w73}
}
EUVIMED